Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples

31 Mar 2010

Abstract excerpt

AT7519 is a potent inhibitor of several cyclin-dependent kinases and is currently in early phase clinical development. Recently, cyclin-dependent kinases 7, 8, and 9 have been shown to regulate transcription through phosphorylation of RNA polymerase II. B-cell lymphoproliferative disorders, including chronic lymphocytic leukemia, rely on the expression of transcripts with a short half-life, such as Mcl-1, Bcl-2,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20354122
DOI: 10.1158/1535-7163.mct-09-1071

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient SamplesPMID 20354122Read ↗

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancerSemantic proximity Read ↗

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell linesSemantic proximity Read ↗

Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcriptionSemantic proximity Read ↗

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabineSemantic proximity Read ↗

VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemiaSemantic proximity Read ↗

Integrated Multi-Omics and Interactome Analysis of CDK8 Inhibition Reveals Erythroid Differentiation Programs and BET Synergy in AML Stem-like CellsSemantic proximity Read ↗

Characterization of molecular and cellular functions of the cyclin‐dependent kinase CDK9 using a novel specific inhibitorSemantic proximity Read ↗

CDK7 inhibitors as anticancer drugsSemantic proximity Read ↗

CDK9 pharmacological inhibition with PRT2527 has antitumor activity in marginal zone lymphoma models and can improve the effects of BTK, PI3K, and BCL2 inhibitorsSemantic proximity Read ↗

CDK9 inhibitors in acute myeloid leukemiaSemantic proximity Read ↗

Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.Semantic proximity Read ↗

Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.